Cystic Fibrosis Pipeline Assessment and Insights Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Cystic Fibrosis: Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

Cystic Fibrosis: Pipeline Assessment and Insights report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.

Key Topics Covered:

Table of Contents:

1.1 List of Tables

1.2 List of Figures

2 Cystic Fibrosis Disease

2.1 Disease Overview

2.1.1 Disease Definition

2.1.2 Disease Epidemiology

2.1.3 Current Treatment Options

2.1.4 Key unmet needs

3 Pipeline Assessment

3.1 Overview

3.2 Strategic Review of the Pipeline

3.3 Pipeline analysis by Phases of Development

3.3.1 NDA/BLA Filed

3.3.2 Phase III Pipeline

3.3.3 Phase II Pipeline

3.3.4 Phase I Pipeline

3.3.5 Preclinical Pipeline

3.3.6 Discovery Pipeline

3.4 Pipeline Analysis by Mechanism of Action

3.5 Pipeline Analysis by Novelty of Mechanism of Action

3.6 Suspended and Terminated products

3.7 Cystic Fibrosis - Promising Therapies in Pipeline

3.7.1 VX-659 + Tezacaftor + Ivacaftor

3.7.2 VX-152 + Tezacaftor + Ivacaftor

3.7.3 VX-440 + Tezacaftor + Ivacaftor

3.7.4 QR-010

3.7.5 ABBV-2222

3.7.6 GLPG1837

Companies Mentioned

  • Eisai
  • moksha8 Pharmaceuticals
  • Daiichi Sankyo
  • UCB
  • Allergan
  • GlaxoSmithKline
  • Aptalis Holdings
  • Eurand
  • Aspen Pharmacare
  • Faes Farma
  • Adare Pharmaceuticals
  • AbbVie
  • Abbott Laboratories
  • Sanofi
  • SciClone Pharmaceuticals
  • NovaMed Pharmaceuticals
  • Otsuka Holdings
  • Esteve
  • Hikma Pharmaceuticals
  • Megapharm
  • Paladin Labs
  • Endo International
  • Ovation Pharmaceuticals
  • Pfizer
  • IMPAX Laboratories
  • Royalty Pharma
  • Northwestern University
  • Marion Merrell Dow
  • Alfresa Holdings
  • Aequus Pharmaceuticals
  • GW Pharmaceuticals
  • Takeda
  • Ovid Therapeutics
  • Marinus Pharmaceuticals
  • Zynerba Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/dzd295/cystic_fibrosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs